Sera Prognostics (NASDAQ:SERA – Get Free Report) and Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.
Risk and Volatility
Sera Prognostics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500.
Profitability
This table compares Sera Prognostics and Bicycle Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sera Prognostics | -47,475.72% | -46.71% | -34.06% |
| Bicycle Therapeutics | -311.11% | -33.22% | -27.79% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for Sera Prognostics and Bicycle Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sera Prognostics | 1 | 0 | 1 | 1 | 2.67 |
| Bicycle Therapeutics | 2 | 3 | 5 | 0 | 2.30 |
Sera Prognostics currently has a consensus price target of $5.50, suggesting a potential upside of 168.29%. Bicycle Therapeutics has a consensus price target of $13.57, suggesting a potential upside of 267.29%. Given Bicycle Therapeutics’ higher possible upside, analysts plainly believe Bicycle Therapeutics is more favorable than Sera Prognostics.
Valuation and Earnings
This table compares Sera Prognostics and Bicycle Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sera Prognostics | $80,000.00 | 1,010.91 | -$31.93 million | ($0.67) | -3.06 |
| Bicycle Therapeutics | $61.20 million | 4.23 | -$218.96 million | ($2.73) | -1.35 |
Sera Prognostics has higher earnings, but lower revenue than Bicycle Therapeutics. Sera Prognostics is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Bicycle Therapeutics beats Sera Prognostics on 10 of the 15 factors compared between the two stocks.
About Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
About Bicycle Therapeutics
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.
